The next two big cases in the field of patent law, the first important post-Bilski matters worth watching, are: Prometheus v. Mayo, and Classen v. Biogen.
Classen involves a patent on methods of determining an immunization schedule.
Prometheus involves a patent on the method of setting the proper dosage of thiopurine to give to patients.
So the action, after KSR and Bilski, is moving to biopharm.
Thiopurine, by the way, is a family of drugs commonly used in the treatment of autoimmune disorders such as Crohn's disease or rheumatoid arthritis.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment